Clinical trials: Open Access
Cytomegalovirus Retinitis, HIV Infections
An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access
To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.
- Trial name
- NCT00002135
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Postoperative Hemorrhage
Aprotinin US Special Access Protocol
This is a special access protocol that will allow physicians access to aprotinin during the temporary marketing suspension. The program will provide aprotinin for treatment of surgical patients undergoing coronary artery bypass…
- Trial name
- NCT00611845
- Testing
- Aprotinin (Trasylol, BAYA0128)
- Where
- 17 sites in United States
- Sponsor
- Bayer
Sickle Cell Disease
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
The intent of this open-label, multicenter expanded access program (EAP) is to provide early access to voxelotor prior to market authorization
- Trial name
- NCT03943615
- Testing
- Voxelotor
- Where
- 18 sites in United States
- Sponsor
- Pfizer
Dementia With Lewy Bodies
Expanded Access Program for CT1812 (Zervimesine)
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
- Trial name
- NCT06961760
- Testing
- zervimesine
- Where
- 8 sites in United States
- Sponsor
- Cognition Therapeutics
Psoriasis
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately responded to prior psoriasis therapy.
- Trial name
- PRIDE (NCT00513370)
- Testing
- Humira (adalimumab)
- Where
- 27 sites in Canada
- Volunteers
- 203 people
- Sponsor
- Abbott
Healthy
AZD Single Ascending Dose Study In Healthy Japanese Subjects
This is a single centre, open label, non-randomised study to access the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3043 following a single dose administration to Japanese subjects.
- Trial name
- JSAD (NCT01028040)
- Testing
- AZD3043
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Indication of the Parent Protocol
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a…
- Trial name
- NCT07456891
- Testing
- Remibrutinib
- Where
- 43 sites in Bulgaria, Canada and 7 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Haemophilia A (Moderate or Severe)
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study…
- Trial name
- LIBERTY (NCT06716814)
- Testing
- Efanesoctocog alfa
- Where
- 20 sites in Bulgaria, France and 5 more
- Volunteers
- 89 people
- Sponsor
- Swedish Orphan Biovitrum
Renal Failure Chronic Requiring Hemodialysis
Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
Compare the HeRO Vascular Access Device to a conventional ePTFE graft.
- Trial name
- NCT00890045
- Testing
- HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft
- Where
- 11 sites in United States
- Volunteers
- 72 people
- Sponsor
- Merit Medical Systems, Inc.
Non-Small Cell Lung Cancer
An EAP Treatment Protocol of Zipalertinib
"Only licensed physicians may submit an email inquiry/question about Taiho's Zipalertinib Expanded Access Program via email (Zipalertinib@parexel.com). If you are a patient or caregiver, do not email Parexel or Taiho.
- Trial name
- NCT07601399
- Testing
- Zipalertinib
- Sponsor
- Taiho Oncology, Inc.
Pulmonary Arterial Hypertension
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1.
- Trial name
- NCT06321705
- Testing
- CS1
- Where
- Sweden
- Sponsor
- Cereno Scientific AB
Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma
Axicabtagene Ciloleucel Expanded Access Study
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
- Conditions
- Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory Transformed Follicular Lymphoma, Relapsed/Refractory High-Grade B-Cell Lymphoma
- Trial name
- ZUMA-9 (NCT03153462)
- Testing
- Axicabtagene Ciloleucel
- Where
- 15 sites in United States
- Sponsor
- Kite, A Gilead Company
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Cholangiocarcinoma
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA).
- Trial name
- ProvIDHe (NCT05876754)
- Testing
- Ivosidenib Oral Tablet
- Where
- 84 sites in Armenia, Australia and 14 more
- Volunteers
- 299 people
- Sponsor
- Servier Affaires Médicales
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Primary: The primary objective of this study under the original protocol was to provide neuromuscular specialists and neurologists access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus…
- Conditions
- Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
- Trial name
- EAP-001 (NCT02189720)
- Testing
- Amifampridine Phosphate
- Where
- United States
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Myelofibrosis (MF)
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger.
- Trial name
- TRANSFORM-2 (NCT04468984)
- Testing
- Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
- Where
- 229 sites in United States, Australia and 28 more
- Volunteers
- 330 people
- Sponsor
- AbbVie
Colorectal Cancer
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared…
- Trial name
- AndroMETa-CRC (NCT07525206)
- Testing
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 990 people
- Sponsor
- AbbVie
Hematological Malignancies
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
- Trial name
- NCT04260698
- Testing
- omidubicel
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gamida Cell ltd
Kidney Stone
Robotic-assisted Percutaneous Access
This is a first-in-man (FIM) study to show feasibility and safety profile of the newly developed robotic device for percutaneous access in PCNL surgery.
- Trial name
- NCT04435132
- Testing
- PCL under fluoroscopy with the aid of the robotic device
- Where
- Malaysia
- Volunteers
- 5 people
- Sponsor
- NDR Medical Technology Pte Ltd
Carcinoma, Non-Small-Cell Lung
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
To provide expanded access and to evaluate the safety, tolerability and efficacy of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR)…
- Trial name
- NCT01931306
- Testing
- Afatinib
- Where
- 8 sites in South Korea
- Sponsor
- Boehringer Ingelheim